Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community

- New open-label extension data from the Phase 2 OASIS trial for etrasimod in ulcerative colitis

- Arena sponsored breakfast symposium: Will oral therapies change the IBD treatment landscape?

- Visit Arena in the exhibit hall at booth #78

SAN DIEGO, Oct. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderately to severely active ulcerative colitis (UC) at the 25^th Annual United European Gastroenterology (UEG) Week. Arena will also present data for olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB₂), in development for the treatment of visceral pain associated with gastrointestinal (GI) diseases. UEG Week is taking place October 19-23, 2019, in Barcelona, Spain.

In addition to the data presentations, Arena is sponsoring a satellite breakfast symposium (details below) and exhibiting at booth #78. Find out more about Arena's ongoing and planned clinical trials in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

Arena Sponsored Breakfast Symposium Details:  
Title:  Will oral therapies change the IBD treatment landscape?
Speakers: Professor Stefan Schreiber (Chair), Professor Ailsa Hart, & Professor Laurent Peyrin-Biroulet
Day/Time: Tuesday, October 22, at 7:00am CEST
Location: Fira Gran Via, Hall 8 – Room A1
How: Learn more and register here

Etrasimod Presentation Details:
Title: Long-term Efficacy and Safety of Etrasimod for Ulcerative Colitis:  Results from the Open- label Extension of the Oasis Study
Session Date/Time:  Monday, October 21, from 10:30 AM – 5:00 PM CEST
Presentation Time: 12:30 – 1:30 PM CEST
Presenting Author:  Dr. Séverine Vermeire
Location:  Poster Hall 7
Poster Identification:  #P0403

Olorinab Presentation Details:
Title: Preclinical and Clinical Efficacy of Olorinab, a Peripherally Restricted, Highly Selective Full Agonist of the Cannabinoid Receptor 2 for the Management of Visceral Pain in Inflammatory Bowel Disease
Session Date/Time:  Tuesday, October 22, from 10:30 AM – 12:00 PM CEST
Presenting Author:  Dr. Peter Higgins
Location:  Hotspot
Abstract Identification:  #OP212

About Etrasimod
Etrasimod (APD334) is a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, discovered by Arena, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes 1, 4 and 5. Etrasimod has therapeutic potential in immune and inflammatory-mediated diseases such as ulcerative colitis, Crohn's disease, and atopic dermatitis. S1P receptors have been demonstrated to be involved in the modulation of several biological responses, including lymphocyte trafficking from lymph nodes to the peripheral blood. By isolating subpopulations of lymphocytes in lymph nodes, fewer immune cells are available in the circulating blood to effect tissue damage.